Christopher Hite

Vice Chairman

Chris has over 25 years of experience advising biopharmaceutical companies on mergers and acquisitions and capital formation. Prior to joining Royalty Pharma in 2020, Chris was an investment banker at Citi where he was the Global Head of Healthcare for nearly 12 years and most recently a vice chairman of Banking, Capital Markets and Advisory (“BCMA”) and also sat on the Executive Committee of BCMA. Prior to joining Citi, Chris was the Global Head of Healthcare Investment Banking at Lehman Brothers.  Chris serves on the Board of Trustees at Lehigh University, the Board of Advisors of Faster Cures, a center of the Milken Institute, and served on the Board of Directors of Acceleron Pharma Inc. (Nasdaq: XLRN) until its acquisition by Merck in November 2021 for $11.5 billion. Chris has a BS from Lehigh University and a JD and MBA from the University of Pittsburgh.

Stay up to date

Subscribe to Royalty Pharma news and alerts